Debiopharm International SA
- Country
- 🇨🇭Switzerland
- Ownership
- Subsidiary
- Established
- 1979-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://debiopharm.com
Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 6
- Registration Number
- NCT01500772
- Locations
- 🇩🇪
Novartis Investigational Site, Mainz, Germany
🇬🇧Novartis Investigative Site, London, United Kingdom
🇺🇸Novartis Investigational site, Bradenton, Florida, United States
Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 44
- Registration Number
- NCT01467882
- Locations
- 🇺🇸
Swedish Pediatric Specialist, Seattle, Washington, United States
🇨🇱IDIMI, Santiago, Chile
🇲🇽Hospital Universitario de Monterrey, Monterrey, Mexico
Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1
- Conditions
- Interventions
- First Posted Date
- 2011-10-05
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 8
- Registration Number
- NCT01446250
- Locations
- 🇺🇸
Novartis Investigational Site, Baltimore, Maryland, United States
Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
- Conditions
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 1081
- Registration Number
- NCT01318694
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
- Conditions
- Interventions
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 340
- Registration Number
- NCT01215643
- Locations
- 🇺🇸
The North Texas Research Institute, Arlington, Texas, United States
🇺🇸Saint Louis University, St. Louis, Missouri, United States
🇺🇸Liver Associates of Texas, Houston, Texas, United States
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
- Conditions
- Interventions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 459
- Registration Number
- NCT01183169
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom
Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2014-02-03
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 81
- Registration Number
- NCT01168752
- Locations
- 🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷Institut Gustave Roussy, Villejuif, France
🇫🇷Centre Georges-François Leclerc, Dijon, France
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2010-03-02
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 51
- Registration Number
- NCT01078649
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2014-10-23
- Lead Sponsor
- Debiopharm International SA
- Registration Number
- NCT00869115
A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
- Conditions
- Interventions
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Debiopharm International SA
- Target Recruit Count
- 290
- Registration Number
- NCT00854802
- Locations
- 🇫🇷
C.H.U Hôpital Cochin, Paris, France
🇫🇷C.H.U de Nancy-Hôpital Brabois, Vandoeuvre-les-Nancy, France
🇫🇷C.H.U de Lyon Hôpital de l'Hôtel Dieu, Lyon, France